Next Article in Journal
The Significance of Mesophilic Aeromonas spp. in Minimally Processed Ready-to-Eat Seafood
Next Article in Special Issue
Nontuberculous Mycobacteria Persistence in a Cell Model Mimicking Alveolar Macrophages
Previous Article in Journal
Field Based Assessment of Capsicum annuum Performance with Inoculation of Rhizobacterial Consortia
Previous Article in Special Issue
MmpL Proteins in Physiology and Pathogenesis of M. tuberculosis
Open AccessReview

Mycobacterium abscessus: Environmental Bacterium Turned Clinical Nightmare

School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK
Birmingham Children’s Hospital, Birmingham Women’s and Children’s NHS Foundation Trust, Steelhouse Lane, Birmingham B4 6NH, UK
Author to whom correspondence should be addressed.
Microorganisms 2019, 7(3), 90;
Received: 27 January 2019 / Revised: 15 March 2019 / Accepted: 19 March 2019 / Published: 22 March 2019
PDF [1790 KB, uploaded 22 March 2019]


Mycobacteria are a large family of over 100 species, most of which do not cause diseases in humans. The majority of the mycobacterial species are referred to as nontuberculous mycobacteria (NTM), meaning they are not the causative agent of tuberculous (TB) or leprosy, i.e., Mycobacterium tuberculous complex and Mycobacterium leprae, respectively. The latter group is undoubtedly the most infamous, with TB infecting an estimated 10 million people and causing over 1.2 million deaths in 2017 alone TB and leprosy also differ from NTM in that they are only transmitted from person to person and have no environmental reservoir, whereas NTM infections are commonly acquired from the environment. It took until the 1950′s for NTM to be recognised as a potential lung pathogen in people with underlying pulmonary disease and another three decades for NTM to be widely regarded by the medical community when Mycobacterium avium complex was identified as the most common group of opportunistic pathogens in AIDS patients. This review focuses on an emerging NTM called Mycobacterium abscessus (M. abs). M. abs is a rapidly growing NTM that is responsible for opportunistic pulmonary infections in patients with structural lung disorders such as cystic fibrosis and bronchiectasis, as well as a wide range of skin and soft tissue infections in humans. In this review, we discuss how we came to understand the pathogen, how it is currently treated and examine drug resistance mechanisms and novel treatments currently in development. We highlight the urgent need for new and effective treatments for M. abs infection as well as improved in vivo methods of efficacy testing. View Full-Text
Keywords: Mycobacterium abscessus; non-tuberculous mycobacteria; antimicrobial drug discovery; cystic fibrosis Mycobacterium abscessus; non-tuberculous mycobacteria; antimicrobial drug discovery; cystic fibrosis

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Lopeman, R.C.; Harrison, J.; Desai, M.; Cox, J.A.G. Mycobacterium abscessus: Environmental Bacterium Turned Clinical Nightmare. Microorganisms 2019, 7, 90.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Microorganisms EISSN 2076-2607 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top